Controversies in Ulcerative Colitis: A Survey Comparing Decision Making of Experts Versus Community Gastroenterologists

Clinical Gastroenterology and Hepatology

Volumn 7, Issue 2, 2009, Pages

  Spiegel, Brennan M R ^a,b,c,d   Ho, Wayne ^a   Esrailian, Eric ^b,c   Targan, Stephan ^e   Higgins, Peter D R ^f   Siegel, Corey A ^g   Dubinsky, Marla ^e   Melmed, Gil Y ^e  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; BALSALAZIDE; CYCLOSPORIN A; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; SALAZOSULFAPYRIDINE; STEROID;

ADD ON THERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CHROMOENDOSCOPY; CLINICAL DECISION MAKING; COLON CANCER; COLON RESECTION; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONSULTATION; CROHN DISEASE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG INDICATION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; GASTROENTEROLOGY; GASTROINTESTINAL DYSPLASIA; HEALTH SURVEY; HOSPITAL PATIENT; HUMAN; LOW DRUG DOSE; MEDICAL EXPERT; MEDICAL SPECIALIST; NARROW BAND IMAGING; REMISSION; STEROID THERAPY; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; VIGNETTE;

EID: 58849134559     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2008.08.029     Document Type: Article

References (31)

1. Pallis A.G., and Mouzas I.A. Instruments for quality of life assessment in patients with inflammatory bowel disease. Dig Liver Dis 32 (2000) 682-688
2. Caellas F., Lopez-Vivancos J., Vergara M., et al. Impact of inflammatory bowel disease on health-related quality of life. Dig Dis 17 (1999) 208-218
3. Irvine E.J. Quality of life of patients with ulcerative colitis: past, present, and future. Inflamm Bowel Dis 14 (2008) 554-565
4. Kornbluth A., and Sachar D. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Patterns Committee. Am J Gastroenterol XX (2004) 1371
5. Society for Surgery of the Alimentary Tract. SSAT patient care guidelines: management of ulcerative colitis. J Gastrointest Surg 11 (2007) 1203-1206
6. Itzkowitz S.H., Present D.H., and Crohn's and Colitis Foundation of America Colon Cancer in IBD Study Group. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 11 (2005) 314-321
7. Carter M.J., Lobo A.J., Travis S.P., et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 53 Suppl 5 (2004) V1-V16
8. Esrailian E., Spiegel B.M.R., Targownik L., et al. Differences in the management of Crohn's disease among experts and community providers, based on a national survey of sample case vignettes. Aliment Pharmacol Ther 26 (2007) 1005-1018
9. Chassin M.R., Kosecoff J., Park R.E., et al. Does inappropriate use explain geographic variations in the use of health care services: a study of three procedures. JAMA 258 (1987) 2533-2537
10. Tobler H.G., Sethi G.K., Grover F.L., et al. Variations in processes and structures of cardiac surgery practice. Med Care 33 (1995) OS43-OS58
11. Spiegel B.M., Farid M., Esrailian E., et al. Appropriateness of diagnostic testing in IBS: provider beliefs do not match published guidelines. Gastroenterology 130 (2006) S1134
12. Spiegel B.M., Gralnek I.M., Laine L., et al. Adherence to "best practices" in nonvariceal upper GI hemorrhage (NVUGIH): a national vignette survey of experts versus community providers. Gastroenterology 132 Suppl 2 (2007) A-29
13. Brook R.H., and Lohr K.N. Efficacy, effectiveness, variations, and quality boundary-crossing research. Med Care 23 (1985) 710-722
14. Brook R.H., McGlynn E.A., and Shekelle P.G. Defining and measuring quality of care: a perspective from US researchers. Int J Qual Health Care 12 (2000) 281-295
15. Wennberg J.E. Practice variations and health care reform: connecting the dots. Health Aff (Millwood) Suppl WebExclusive:VAR140-4 (2004)
16. In: Fitch K., Bernstein S.J., Aguilar M., et al. (Eds). RAND/UCLA appropriateness method user's manual (2001), RAND, Santa Monica, CA
17. Winawer S., Fletcher R., Rex D., et al. AGA guidelines: colorectal cancer screening and surveillance. Gastroenterology 124 (2003) 544
18. Eaden J.A., and Mayberry J.F. Guidelines for screening and surveillance of asymptomatic colorectal cancer in patients with inflammatory bowel disease. Gut 51 Suppl 5 (2002) V10
19. Bergman R., and Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 23 (2006) 841-855
20. Sutherland L., and MacDonald J.K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 3 (2003) CD000543
21. Munkolm P., Loftus Jr. E.V., Reinacher-Schick A., et al. Prevention of colorectal cancer in inflammatory bowel disease: value of screening and 5-aminosalicylates. Digestion 73 (2006) 11-19
22. Giannini E.G., Kane S.V., Testa R., et al. 5-ASA and colorectal cancer chemoprevention in inflammatory bowel disease: can we afford to wait for "best evidence"?. Dig Liver Dis 37 (2005) 723-731
23. Velayos F., and Mahadevan U. Management of steroid-dependent ulcerative colitis: immunomodulatory agents, biologics, or surgery?. Clin Gastroenterol Hepatol 5 (2007) 668-671
24. Melmed G.Y., Elsahoff R., Chen G.C., et al. Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study. Clin Gastroenterol Hepatol 5 (2007) 602-608
25. Lichtiger S., Present D.H., Kornbluth A., et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330 (1994) 1841-1845
26. Jarnerot G., Hertevig E., Friis-Liby I., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128 (2005) 1805-1811
27. Van Assche G., D'Haens G., Noman M., et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 125 (2003) 1025-1031
28. Kohn A., Daperno M., Armuzzi A., et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 26 (2007) 747-756
29. Colliver J.A., and Swartz M.H. Assessing clinical performance with standardized patients. JAMA 278 (1997) 790-791
30. Luck J., Peabody J.W., Dresselhaus T.R., et al. How well does chart abstraction measure quality?. a prospective comparison of standardized patients with the medical record. Am J Med 108 (2000) 642-649
31. Peabody J.W., Luck J., Glassman P., et al. Measuring the quality of physician practice by using clinical vignettes: a prospective validation study. Ann Intern Med 141 (2004) 771-780